Transformable acupoint injection ligustrazine medicine and method for preparing same
A technology of acupoint injection and ligustrazine medicine, which is applied in the field of transformable acupoint injection medicine and its preparation, can solve the problems of non-biodegradation, application limitation and the like, and achieves the effects of simple and easy operation, high compliance and good curative effect.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0034]The preparation method of transformable acupoint injection ligustrazine medicine comprises the following steps:
[0035] 1) Dissolve chitosan in 0.1M acetic acid solution to prepare a chitosan acetic acid solution with a concentration of 2.3wt% (mass) (stir with a magnetic stirrer for about 1 hour to fully dissolve it in acetic acid);
[0036] 2) Prepare a dipotassium hydrogen phosphate solution with a concentration of 14.75wt% (mass) with deionized water;
[0037] 3) The above-mentioned chitosan acetic acid solution and dipotassium hydrogen phosphate solution were stored in a refrigerator at 4°C for about 0.5 hours;
[0038] 4) According to the ratio of each raw material: ligustrazine: chitosan acetic acid solution: dipotassium hydrogen phosphate solution = 2mg: 1mL: 1mL, choose ligustrazine, chitosan acetic acid solution and dipotassium hydrogen phosphate solution and mix to obtain Transformable point injection of Ligustrazine drug (sol).
[0039] Application: The tr...
Embodiment 2
[0069] Basically the same as Example 1, the difference is: the concentration of chitosan acetic acid solution is 2wt% (mass). The concentration of dipotassium hydrogen phosphate solution is 14wt% (mass).
[0070] Application: The transformable acupoint injection of ligustrazine drug is currently being used in scientific research and experimental research to observe its effect on MMP-9 and TIMP-1 in the cortical area of focal cerebral ischemia-reperfusion rats. The process and conditions of MMP-9 and TIMP-1 experiments. Effect is the same as embodiment 1.
Embodiment 3
[0072] Basically the same as Example 1, the difference is: the concentration of chitosan acetic acid solution is 2.5wt% (mass). The concentration of dipotassium hydrogen phosphate solution is 15wt% (mass).
[0073] Application: The transformable acupoint injection of ligustrazine drug is currently being used in scientific research and experimental research to observe its effect on MMP-9 and TIMP-1 in the cortical area of focal cerebral ischemia-reperfusion rats. The process and conditions of MMP-9 and TIMP-1 experiments. Effect is the same as embodiment 1.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 